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OBJECTIVE—Optimal glucose homeostasis requires exquisitely
precise adaptation of the number of insulin-secreting b-cells in
the islets of Langerhans. Insulin itself positively regulates b-cell
proliferation in an autocrine manner through the insulin receptor
(IR) signaling pathway. It is now coming to light that cannabinoid
1 receptor (CB1R) agonism/antagonism inﬂuences insulin action
in insulin-sensitive tissues. However, the cells on which the
CB1Rs are expressed and their function in islets have not been
ﬁrmly established. We undertook the current study to investigate
if intraislet endogenous cannabinoids (ECs) regulate b-cell pro-
liferation and if they inﬂuence insulin action.
RESEARCH DESIGN AND METHODS—We measured EC
production in isolated human and mouse islets and b-cell line
in response to glucose and KCl. We evaluated human and mouse
islets, several b-cell lines, and CB1R-null (CB1R
2/2) mice for the
presence of a fully functioning EC system. We investigated if ECs
inﬂuence b-cell physiology through regulating insulin action and
demonstrated the therapeutic potential of manipulation of the EC
system in diabetic (db/db) mice.
RESULTS—ECs are generated within b-cells, which also ex-
press CB1Rs that are fully functioning when activated by ligands.
Genetic and pharmacologic blockade of CB1R results in en-
hanced IR signaling through the insulin receptor substrate 2-
AKT pathway in b-cells and leads to increased b-cell proliferation
and mass. CB1R antagonism in db/db mice results in reduced
blood glucose and increased b-cell proliferation and mass, cou-
pled with enhanced IR signaling in b-cells. Furthermore, CB1R
activation impedes insulin-stimulated IR autophosphorylation on
b-cells in a Gai-dependent manner.
CONCLUSIONS—These ﬁndings provide direct evidence for
a functional interaction between CB1R and IR signaling involved
in the regulation of b-cell proliferation and will serve as a basis for
developing new therapeutic interventions to enhance b-cell func-
tion and proliferation in diabetes. Diabetes 60:1198–1209, 2011
I
nsulin is the prime mediator of glucose homeostasis.
A paucity (as occurs in type 1 diabetes) or surplus
(due to excessive exogenous insulin administration
or insulin-secreting tumors) of insulin causes so-
matic damage by energy deprivation and neuroglucopenic
brain damage. Therefore, the number of insulin-secreting
b-cells is tightly regulated to maintain a very narrow blood
glucose range. Intriguingly, insulin also has major effects
on its own secretory cells. Exogenously infused insulin
increases b-cell mass (1), and mice lacking b-cell insulin
receptors (IRs) develop insulin-dependent diabetes be-
cause of insufﬁcient b-cell proliferation and defective in-
sulin secretion (2,3). IR activation on b-cells, in addition to
being necessary for optimal function of the glucose sens-
ing machinery (3), causes phosphorylation of insulin re-
ceptor substrate 2 (IRS2), which then transduces the signal
to the AKT-forkhead box protein O1 (FoxO1) cascade and
increases b-cell proliferation (4).
Theendogenouscannabinoids(ECs),2-arachidonoylglycerol
(2-AG), and anandamide (AEA), are lipid transmitters
synthesized only on demand by Ca
2+-dependent enzymes
in the brain and the periphery (5,6). The biologic effects
of ECs are mediated by two G protein-coupled receptors
(CB1R and CB2R) that use the Gai class of heterotrimeric
proteins to regulate intracellular signaling pathways (5).
ECs are key players of feeding behavior through the ac-
tivation of the CB1Rs in the brain (5). Initial studies
found that CB1Rs are expressed mainly in the brain and
modulate food intake and energy balance.
However, new evidence has accumulated that suggests
that ECs also inﬂuence insulin action through peripheral
CB1Rs in insulin-sensitive tissues, such as adipose tissue,
liver, and muscle, and that these effects are independent of
food intake or central CB1R activation (6). Indeed, AEA
impairs insulin-stimulated AKT phosphorylation and de-
creases glucose uptake in skeletal muscle cells (7), and
CB1R antagonism enhances insulin responsiveness of
skeletal muscle (8). However, the mechanism by which
CB1R regulates insulin action remains unknown.
Recent studies have extended this notion to the endo-
crine pancreas, where CB1Rs and EC metabolic enzymes
were found in rodent and human islets (9–15). The cells on
which CB1Rs are expressed have not been ﬁrmly estab-
lished, however. Initial studies suggested that CB1Rs are
densely located in a-cells and to a lesser degree in b-cells
(10,11), another reported the absence of CB1R in b-cells
(13), whereas still other reports point to the presence of
CB1R in b-cells (9,12,14,15). The presence of CB2R in
b-cells is also controversial. Studies reported the presence
of CB2R in b-cells (9,11,15), whereas other studies pointed
to the absence of CB2R in b-cells (10,12). Here, we tried
to settle the controversy over the existence of the EC
receptors in b-cells and provide a novel, fundamental, and
potentially exploitable function for CB1Rs in insulin-
mediated b-cell proliferation. We found that an intraislet
EC system (ECS) indeed exists and serves as a negative
feedback on insulin-mediated b-cell proliferation. We also
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ORIGINAL ARTICLEdemonstrate the therapeutic potential of manipulation of
the ECS in a mouse model of type 2 diabetes.
RESEARCH DESIGN AND METHODS
Materials. Sources and dilutions of primary antibodies used in immunoblot-
ting, immunoprecipitation, and immunostaining are listed in Supplementary
Table 1. AEA, 2-AG, AEA-d8, 2-AG-d5, WIN55,212-2, arachidonyl-2-
chloroethylamide (ACEA), AM251, and AM630 were obtained from Cayman
Chemical (Ann Arbor, MI). GFP-HA-tagged CB1R was from K. Mackie (Indiana
University). The human IR and Gai3 cDNA were ampliﬁed by RT-PCR from
a human pancreas RNA (Stratagene, La Jolla, CA), with oligo-dT (18 bp) for
the reverse transcription. The IR cDNA was incorporated into a 33Flag vector
and the Gai3 cDNA was incorporated into an mVenus-C1 vector. IR mutant
(IR-3YA), whose Tyr1158/1162/1163 residues were substituted to Ala, was
generated from wild-type IR (IR-WT) using a QuikChange II XL site-directed
mutagenesis kit (Stratagene).
Animal experiments. CB1R
2/2 mice and their WT littermates were de-
veloped and backcrossed to a C57Bl/6 J background, as previously described
(16). The study used male 2- to 3-month-old CB1R
+/+ and CB1R
2/2 mice.
AM251 (10 mg/kg) was administrated by daily intraperitoneal injection to
1-month-old normal C57Bl/6 J mice for 4 weeks. FAAH
2/2 mice were obtained
from Dr. Benjamin Cravatt (Scripps Research Institute), and 1-month-old
db/db mice were from The Jackson Laboratory (Bar Harbor, ME).
DMSO, AM251 (10 mg/kg), and AM630 (10 mg/kg) were injected daily for
4 weeks. Then, the pancreata were dissected and blood was collected in the ad
lib state of eating. Blood glucose concentration was measured using an Elite
glucometer (Bayer Healthcare, Tarrytown NY), and plasma insulin was mea-
sured using a rat/mouse insulin ELISA Kit (Crystal Chem, Downers Grove, IL).
All animal care and experimental procedures followed National Institutes of
Health (NIH) guidelines and were approved by the National Institute on Aging
Animal Care and Use Committee.
Immunostaining and pancreas morphometry. Pancreata were ﬁxed in 4%
paraformaldehyde, immersed in 20% sucrose before freezing, and sectioned
(7-mm thickness). Human and mouse parafﬁn-embedded pancreatic sections
were immunostained as before (17). After antigen unmasking, the slides were
incubated with primary antibodies (Supplementary Table 1), followed by
secondary antibodies (Invitrogen, Carlsbad, CA) along with TO-PRO-3 (Invi-
trogen), in some cases, for nuclear staining.
Slides were viewed using a LSM-710 confocal microscope (Carl Zeiss
MicroImaging, München-Hallbergmoos, Germany). Multiple sections from 3 to
5 mice per group, separated by at least 200 mm from each section, were
assessed for signal intensity and the number of nuclear p27- or proliferating
cell nuclear antigen (PCNA)-positive (PCNA
1) b-cells with LSM Image Browser
software (Carl Zeiss). To determine b-cell area and mass, the pancreata were
trimmed of all nonpancreatic tissue and processed for immunostaining. The
cross-sectional areas of pancreata and b-cells were determined from multiple
sections (n = 5 mice per group), separated by at least 200 mm from each sec-
tion, using LSM Image Browser software. The relative cross-sectional area of
b-cells was determined by quantiﬁcation of the cross-sectional area covered by
insulin-positive cells divided by the cross-sectional area of total pancreas tissue.
The b-cell mass per pancreas was estimated as the product of the relative
cross-sectional area of b-cells per total tissue and the weight of the pancreas.
Islet isolation and EC levels. Human islets were provided by the Islet Cell
Resource Center. Mouse islets were isolated using collagenase digestion, as we
previously described (18). Human or mouse islets in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 4 mmol/L glucose and 1% BSA were
pelleted and incubated with DMEM containing 4, 10, or 15 mmol/L glucose,
with or without KCl (30 mmol/L) for 10 min. Lipid extraction and tandem mass
spectrometry analysis were done next, and details are described in the
Supplementary Data.
Laser capture microdissection of b-cells. We used the PixCell II Work-
station (Arcturus Engineering, Carlsbad, CA) to perform laser capture mi-
crodissection and image acquisition of b-cells in pancreas sections, as we
previously described (17). Total RNAs were isolated using the PicoPure RNA
Isolation Kit (Arcturus), according to the manufacturer’s instructions. After
reverse transcription, the resulting materials were used for quantitative (q)RT-
PCR ampliﬁcation using gene-speciﬁc primer pairs and SYBR Green PCR
master mix (Applied Biosystems, Carlsbad, CA).
Cell culture, transfection, and proliferation studies. b-IRWT and b-IRKO
cells were established from mice (2,19,20). b-IRWT, b-IRKO, MIN6, b-TC6, and
a-TC1 cells were maintained in DMEM with 10% FBS (Invitrogen). CHO-K1
and CHO-IR (CHO-K1 cells stably transfected with IR) cells were maintained
in DMEM/F-12 with 10% FBS. Human neuroblastoma BE(2)-M17 cells were
maintained in OPTI-MEM with 10% FBS. Transfections of small interfering (si)
RNAs (Santa Cruz Biotechnology, Santa Cruz, CA) for Gai3 and CB1R and the
expression vectors for CB1R, Gai3, and IR were done using lipofectamine
RNAiMAX or 2000 (Invitrogen). Scramble siRNA (Silencer Negative Control
#1; Ambion, Austin, TX) or empty vector was transfected as the negative
control. For exogenous insulin treatment, cells starved overnight in low-
glucose DMEM containing 0.1% FBS were incubated for 2 h in glucose-free
DMEM with 0.1% BSA, followed by pretreatment with CB1R agonists for
15 min and insulin stimulation for 10 min, with or without CB1R agonists. For
cell proliferation studies, cells were plated into 96-well plates with complete
medium. After treatment with CB1R antagonist or agonists, or both, the
proliferation rate was determined after 48 or 72 h using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI),
according to the manufacturer’s instructions.
Immunoprecipitation and Gai activation assay. Cell lysates extracted us-
ing radioimmunoprecipitation assay buffer (RIPA) containing protease and
phosphatase inhibitor cocktails were incubated with the appropriate antibody
and subsequently incubated with protein A/G beads. Beads were washed three
times with RIPA buffer and underwent Western blot analysis with the primary
antibodies and with an HRP-conjugated secondary antibody. Blots were vi-
sualizedbyenhancedchemiluminescence(GEHealth, Berne,Switzerland). For
Gai activation assay, we used the Gai Activation Assay Kit (NewEast Bio-
sciences, Malvern, PA) as previously described (21). Cells treated with or
without ACEA were lysed with ice-cold 13Assay/Lysis buffer and underwent
immunoprecipitation with anti-Gai–guanosine triphosphate (GTP) antibody
and Western blot analysis with anti-Gai3 antibody. For positive control,
b-IRWT cell lysate, not treated with ACEA, was incubated with guanosine 5’-O-
[g-thio] triphosphate (GTP-gS) for 90 min before immunoprecipitation.
Statistical analysis. Quantitative data are presented as the mean 6 SEM.
Differences between mean values were compared statistically by Student
t test. Comparisons were performed by using GraphPad Prism (GraphPad
Software, La Jolla, CA). A P value of , 0.05 was considered statistically sig-
niﬁcant.
RESULTS
Islets have a self-contained ECS. CB1Rs are present in
b- and a-cells in both mouse (Fig. 1A) and human (Fig. 1B)
islets. To conﬁrm speciﬁcity of staining, we used pancreata
from CB1R
2/2 mice (16) (Fig. 1A) and the corresponding
blocking peptides (Fig. 1A). For added proof of our ﬁnd-
ings, we microdissected b-cells from islets of CB1R
+/+ and
CB1R
2/2 mice by laser-capture microscopy, and using
qRT-PCR of the captured cells, we conﬁrmed CB1R ex-
pression (Fig. 1C). Western blot analysis showed that
CB1Rs are expressed in mouse insulinoma (b-TC6 and
MIN6) and glucagonoma (a-TC1) cells (Supplementary
Fig. 1A). CB2Rs are absent in b-a n da-cells, but cellular
CB2R staining is evident in islets (Fig. 1D). Of general
interest, and as previously reported (10), the CB2Rs
are present in somatostatin-containing cells in islets
(Fig. 1E).
Also as previously reported (11), EC-synthetic enzymes,
N-acyl-phosphatidyl ethanolamine phospholipase D (NAPE-
PLD; Fig. 2A) and diacylglycerol lipase-a (DAGLa) (Fig.
2B) are present mainly in b-cells, with little if any ex-
pression in a-cells in both human and mouse islets. The
EC-degrading enzyme, fatty acid amide hydrolase (FAAH),
is present mainly in b-cells (Fig. 2C), and monoacyl glyc-
erol lipase (MAGL) is present in both b-a n da-cells (Fig.
2D) in human and mouse islets. In agreement with pub-
lished literature (9,10), increasing glucose concentrations
increased 2-AG and AEA levels in human (Fig. 2E) and
mouse (Fig. 2F) islets, and membrane depolarization with
KCl also increased 2-AG and AEA levels in human islets
(Fig. 2E). Consistently, glucose and KCl also increased 2-
AG levels in insulin-secreting immortalized b-cells (b-IRWT)
established from mice (2,19,20) (Supplementary Fig. 1B).
Thus, these results favor the presence of an entire self-
contained ECS in mouse and human islets.
Enhanced IR signaling and b-cell proliferation due to
CB1R antagonism. The CB1R
2/2 mice are known to have
a lean phenotype and are resistant to weight gain, even
W. KIM AND ASSOCIATES
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tolerance and insulin sensitivity compared with WT mice
(22,23). Consistently, treatment with CB1R ligands leads
to glucose intolerance and insulin resistance in rodents
(23–25) and conversely, peripheral, but not central, CB1R
antagonism caused weight-independent improvement in
glucose tolerance, insulin sensitivity, fatty liver, and plasma
lipid proﬁle even in mice with genetic or diet-induced obe-
sity (23,25,26). These effects are independent of food intake
or central CB1R activation (6,23,26).
Their pancreata have not been previously studied. We
found that the amount of phosphorylated IR at Y1162/1163
(p-IR), IRS1/2 at Y612 (p-IRS1/2), and AKT at S473 (p-AKT)
were all higher in the islets of CB1R
2/2 mice compared
with age-matched CB1R
+/+ mice (Fig. 3A). Because IR sig-
naling is a key regulator of b-cell proliferation (1–4,27–29), we
investigated b-cell area and islet size in CB1R
2/2 mice. In
keeping with enhanced IR signaling in isolated islets of
CB1R
2/2 mice, b-cell area (Fig. 3B) and islet size (Fig. 3C),
but not pancreas wet weight of CB1R
+/+ (0.216 g 6 0.02 g)
versus CB1R
2/2 (0.196 6 0.02 g, n = 6 per genotype, P =
0.48), were increased, and the distribution of islet size
(Fig. 3D) was shifted toward bigger islets in CB1R
2/2
compared with CB1R
+/+ mice. PCNA, a marker of cell
proliferation, was more readily apparent in nuclei of
b-cells in CB1R
2/2 mice than in CB1R
+/+ mice (Fig. 3E).
Ki-67 staining, another marker of cell proliferation, gener-
ated similar results (data not shown). Concordant with
these observations, CB1R blockade by AM251 also led to
increases in b-cell area (Fig. 3F)a n dP C N A
+ b-cells (Fig. 3G),
compared with DMSO-treated animals.
CB1R blockade leads to increased b-cell mass in db/db
mice. Genetic and pharmacologic blockade of CB1R in
mice with diet-induced obesity results in improved
FIG. 1. The presence of CB1R in pancreatic b-cells. A: Immunostaining for CB1R in pancreatic sections from CB1R
+/+ and CB1R
2/2 mice. Boxed
areas are magniﬁed and shown on the bottom panel. Scale bar = 50 mm. B: Immunostaining for CB1R in human islets. The speciﬁcity of anti-CB1R
antibody was assessed by antigen preabsorption with the corresponding blocking peptides. Boxed areas are magniﬁed and shown on the bottom
panel. Scale bar = 50 mm. C: qRT-PCR ampliﬁcation of insulin (ins2) and CB1R mRNA from laser-captured b-cells of CB1R
+/+ and CB1R
2/2 mice.
Data were normalized to 18S levels. The upper panel shows a representative image of islets before and after laser capture of b-cells. D: Immu-
nostaining for CB2R in human islets. The speciﬁcity of anti-CB2R antibody was assessed by antigen preabsorption with the corresponding blocking
peptides. Boxed areas are magniﬁed and shown on the bottom panel. Scale bar = 50 mm. E: Immunostaining for somatostatin and CB2R in human
islets. Scale bar = 50 mm. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Because genetic CB1R ablation resulted in larger islets
and enhanced b-cell proliferation, despite improved
insulin sensitivity, we investigated if CB1R modulation
would be beneﬁcial to b-cells in a mouse model of type 2
diabetes. We injected DMSO, AM251, or AM630 (a CB2R
antagonist) daily into 4-week-old db/db mice for 4 weeks
(Fig. 4A). Consistent with previous reports (23,25,26,30),
AM251-treated mice had lower body weight (Fig. 4B)a n d
blood glucose (Fig. 4C) and plasma insulin (Fig. 4D)l e v e l s
than DMSO-treated mice, whereas AM630 had no obvious
effects (Fig. 4B–D). Pancreatic sections showed increased
intraislet insulin content and total b-cell mass in AM251-
treated mice compared with DMSO-treated mice (Fig. 4E–G),
which was most likely due to enhanced b-cell proliferation
(Fig. 4H).
Given that AKT regulates p27
Kip1 (p27) activity, an in-
hibitor of cell cycle progression, by affecting its abundance
and subcellular localization (31,32), and that accumulation
of p27 in the nuclei of b-cells contributes to deﬁcient b-cell
mass and proliferation during the development of type 2
diabetes in Irs2
2/2 and db/db mice (28), we examined the
expression and subcellular localization of p27. Immuno-
staining of pancreatic sections from AM251-treated mice
showed a signiﬁcant decrease in the total amount and
nuclear localization of p27 in b-cells, with most of the
protein being localized in cytoplasm, compared with
DMSO-treated mice (Fig. 4I). To evaluate whether the
FIG. 2. Identiﬁcation of intraislet ECS. A and B: Immunostaining for NAPE-PLD (A) and DAGLa (B) in human and mouse islets. The speciﬁcity of
anti-NAPE-PLD and anti-DAGLa antibodies was assessed by antigen preabsorption with the corresponding blocking peptides. Scale bar = 50 mm.
C: Immunostaining for FAAH in pancreatic sections of human and FAAH
+/+ and FAAH
2/2 mice. Scale bar = 50 mm. D: Immunostaining for MAGL in
human and mouse islets. The speciﬁcity of anti-MAGL antibody was assessed by antigen preabsorption with the corresponding blocking peptides.
Scale bar = 50 mm. E: Levels of AEA and 2-AG extracted from one lot of human islets exposed to the indicated glucose concentrations with or
without KCl for 10 min. The amount of AEA and 2-AG in the samples were determined by calculating the ratio of abundance of AEA or 2-AG to the
internal standard abundance. F: Levels of AEA and 2-AG extracted from mouse islets exposed to the indicated glucose concentrations for 10 min.
The amount of AEA and 2-AG in the samples were determined by calculating the ratio of abundance of AEA or 2-AG to the internal standard
abundance. Data are shown as the mean 6 SEM from two independent experiments. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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associates with any changes in IR signaling, we examined
phosphorylation levels of IR. The amount of p-IR was
signiﬁcantly increased in AM251-treated mice compared
with DMSO-treated mice (Fig. 4G).
CB1R inhibits b-cell proliferation by impeding IR
autophosphorylation. Because pharmacologic and ge-
netic blockade of CB1Rs led to enhanced IR signaling and
b-cell proliferation, we next investigated the potential role
of IRs as a/the mediator of CB1R-controlled b-cell pro-
liferation. We used b-cells established from control (b-IRWT)
and b-cell–speciﬁc IR knockout (b-IRKO) mice (2,19,20) in
which expression levels of CB1Rs are similar (Fig. 5A). The
selective synthetic CB1R agonist ACEA slowed proliferation
of b-IRWT cells that was prevented by AM251 (Fig. 5B).
As previously reported (19), b-IRKO cells already had
signiﬁcantly reduced proliferation rates compared with
b-IRWT cells (Fig. 5C). The proliferation rate of b-IRWT
was increased by AM251 (Fig. 5D) and decreased by ACEA
(Fig. 5E), whereas both compounds had no or a lesser
effect on b-IRKO cells (Fig. 5D and E). Consistently, ACEA
dose-dependently decreased levels of p-IRS1/2, p-AKT, and
p-FoxO1 (Fig. 5F) and increased p27 expression (Fig. 5A)
in b-IRWT cells, but not in b-IRKO cells. CB1R blockade by
AM251 in normal mice also resulted in a signiﬁcant de-
crease in both the amount and nuclear localization of p27
(Fig. 5G) compared with DMSO-treated animals. These
results suggest that CB1R signaling functions as a negative
regulator of the proliferative effects of endogenously se-
creted insulin from b-cells.
FIG. 3. Effects of CB1R antagonism on b-cell proliferation. A: Western blot analysis for the indicated proteins in isolated islets from overnight-
fasted CB1R
+/+ and CB1R
2/2 mice. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. B: Representative
immunostaining for insulin in CB1R
+/+ and CB1R
2/2 mice. Scale bar = 200 mm. Mean b-cell area is shown on the right. C and D: Mean islet size (C)
and islet size distribution (D)o fCB1R
+/+ and CB1R
2/2 mice. The data were estimated from at least 225 islets per genotype. E: Pancreatic sections
of cohorts in panel B, showing PCNA
+ b-cells as indicated by arrows. Scale bar = 50 mm. Quantiﬁcation of PCNA
+ b-cells is shown on the right.T h e
number of cells that are positive for both PCNA and insulin were quantiﬁed as a percentage of the total number of insulin-positive cells in the
sections. F: Representative immunostaining for insulin in DMSO- and AM251-injected mice. Scale bar = 200 mm. Mean b-cell area of DMSO- and
AM251-treated mice is shown on the right. G: Pancreatic sections of cohorts in F, showing PCNA
+ b-cells as indicated by arrows. Scale bar = 50 mm.
Quantiﬁcation of PCNA
1 b-cells is shown on the right. The number of cells that are positive for both PCNA and insulin were quantiﬁed as
a percentage of the total number of insulin-positive cells in the sections. Data are shown as the mean 6 SEM in all panels (n =3 –5 animals per
group). *P < 0.05; **P < 0.01. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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1202 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 4. Increased b-cell mass and proliferation in AM251-treated db/db mice. A: Experimental timeline for DMSO, AM251, or AM630 (CB2R
antagonist) treatment in 4-week-old db/db mice. DMSO, AM251 (10 mg/kg), or AM630 (10 mg/kg), were administrated by daily intraperitoneal
injection for 4 weeks. B: Body weight of DMSO-, AM251-, or AM630-treated db/db mice. C and D: Blood glucose (C) and plasma insulin (D) levels at
the end of the 4-week period. E: Representative images for insulin in db/db mice injected with DMSO or AM251 for 4 weeks. Scale bar = 200 mm.
F: Quantiﬁcation of insulin intensity in islets of cohorts in E. G: Morphometric assessment of b-cell mass of cohorts in E. H: Representative images
of PCNA
+ b-cells in islets of cohorts in E. Arrows denote PCNA
+ b-cells. Scale bar = 50 mm. Quantiﬁcation of PCNA
+ b-cells is shown on the right.
The number of cells that are positive for both PCNA and insulin were quantiﬁed as a percentage of the total number of insulin-positive cells in the
sections. I: Representative immunostaining for insulin and p27 in islets of cohorts in E. Scale bar = 50 mm. Relative signal intensity for p27 in islet
is shown on the right. J: Representative immunostaining for IR and p-IR in islets of cohorts in E. Scale bar = 50 mm. Relative signal intensity for
p-IR in islets is shown on the right. Intensity for p-IR was normalized to that for total IR-b. Data are shown as the mean 6 SEM in all panels (n =5
animals per group). *P < 0.05; **P < 0.01. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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tivity, isolated mouse islets (Fig. 6A) and b-IRWT cells
(Fig. 6B) were pretreated with AEA or 2-AG and ACEA,
respectively, before addition of exogenous insulin. All
agonists markedly prevented exogenous insulin-stimulated
IR autophosphorylation and downstream signaling. This
was also true in BE(2)-M17 human neuroblastoma cells
(data not shown), which express CB1Rs (Supplementary
Fig. 1A). In addition, ACEA diminished exogenous insulin-
stimulated IR autophosphorylation and levels of p-IRS1/2,
p-PDK1, p-AKT, and p-FoxO1 in MIN6 cells (data not
shown). The inhibitory effects of CB1R agonists on IR
autophosphorylation and p-AKT were not observed in CHO
cells (CHO cells lack CB1Rs, see Supplementary Fig. 1A;
Fig. 6C), but ACEA treatment in CHO-IR (CHO cells stably
transfected with IR) cells transfected with the expression
vector containing GFP-HA–tagged CB1R led to reduced IR
autophosphorylation (Fig. 6D).
To directly conﬁrm the inhibitory effects of CB1R on IR
autophosphorylation, we transfected Flag-tagged IR-WT
and IR mutant (IR-3YA), whose Tyr1158/1162/1163 resi-
dues were substituted to Ala (Fig. 6E), into b-IRKO cells
and then treated the cells with ACEA for 40 h (Fig. 6F). IR
autophosphorylation was detected in IR-WT–transfected
b-IRKO cells, presumably due to endogenous insulin se-
cretion, and ACEA reduced levels of p-IR and p-AKT in
FIG. 5. Inhibitory effects of CB1R on b-cell proliferation depends on IR. A: Levels of CB1R, p27, and IR in b-IRWT and b-IRKO cells exposed to
a selective synthetic CB1R agonist ACEA for 40 h. B: Proliferation rates of b-IRWT cells exposed to ACEA with or without AM251 for 48 h. Data are
shown as the mean 6 SEM from three independent experiments. **P < 0.01. C: Proliferation rates of b-IRWT and b-IRKO cells 3 days after plating.
Data are shown as the mean 6 SEM from three independent experiments. **P < 0.01. D: Effects of AM251 on the proliferation of b-IRWT and b-IRKO
cells. Data are shown as the mean 6 SEM from three independent experiments. *P < 0.05; **P < 0.01. E: Effects of ACEA (48 h) on the proliferation
of b-IRWT and b-IRKO cells. Data are shown as the mean 6 SEM from three independent experiments. **P < 0.01. F: Levels of the indicated proteins
in b-IRWT and b-IRKO cells exposed to ACEA for 40 h. G: Representative immunostaining of insulin and p27 in pancreatic sections from DMSO- and
AM251-injected mice. Scale bar = 50 mm. Quantiﬁcation of p27 intensity and nuclear p27
+ b-cells in islets is shown on the bottom. Data are shown as
the mean 6 SEM (n = 3 per group). **P < 0.01. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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levels were not altered (Fig. 6F). In sum, these results
suggest a functional interaction between CB1R and IR
signaling upon IR autophosphorylation.
Inhibitory effect of CB1R on IR signaling depends
on Gai. Activated CB1Rs mediate their intracellular actions
through Gai proteins (5). Gai3 appears to be expressed mainly
in b-cells of both human and mouse (Fig. 7A), and its activity
was increased by CB1R activation in both b-IRWT and
b-IRKO cells (Fig. 7B). ACEA dose-dependently increased
the association between Gai3 and IR (Fig. 7C), whereas
siRNA-mediated attenuation of CB1Rs (Supplementary
Fig. 2A) reduced the association (Fig. 7C). Furthermore,
exogenous insulin treatment led to a decrease in Gai3/IR
association, which was impeded by ACEA (Fig. 7D).
We further conﬁrmed an EC-mediated Gai3/IR associa-
tion using IR-WT and IR-3YA–transfected b-IRKO cells
with or without ACEA treatment for 15 min. As shown in
Fig. 6E, ACEA reduced levels of p-IR and p-AKT in IR-WT–
transfected b-IRKO cells, but p-AKT was not reduced in
IR-3YA–transfected b-IRKO cells (Fig. 7E), and most in-
terestingly, Gai3 association with IR-3YA was actually
increased compared with IR-WT (Fig. 7F and G). ACEA
increased Gai3/IR association (Fig. 7F), which conversely
was reduced by AM251 (Fig. 7G). These results suggest
that Gai mediates the inhibitory effect of CB1R activation
on IR autophosphorylation by its association with IR.
Furthermore, over-expression of Gai3 in b-IRWT cells led
to decreased levels of p-IR and p-IRS1/2 (Fig. 8A) and
knockdown of CB1Rs (Supplementary Fig. 2A)o rG ai3
(Supplementary Fig. 2B) by siRNA in b-IRWT cells abol-
ished the ability of ACEA to inhibit insulin-stimulated
phosphorylation of IR, IRS1/2, and AKT (Fig. 8B) as well
as its ability to increase p27 expression (Fig. 8C). Con-
sistently, knockdown of CB1Rs or Gai3 resulted in an in-
crease in b-cell proliferation (Fig. 8D) and a loss of the
inhibitory actions of ACEA (Fig. 8E). These results suggest
that the CB1R-mediated effects on IR and downstream
signaling involve EC-induced activation of Gai.
DISCUSSION
In contrast to adipose tissue, liver, and muscle, the pres-
ence and effects of CB1Rs in b-cells have been in-
conclusive. Here, we demonstrate that b-cells contain all
of the components of a self-contained ECS: CB1R, the
FIG. 6. Regulation of IR activity by CB1R. A: Phosphorylation levels of p-IR in isolated mouse islets exposed to insulin (10 nmol/L) for 10 min with
vehicle, AEA or 2-AG. B: Western blot analysis of the indicated proteins in b-IRWT cells exposed to insulin (10 min) with ACEA or vehicle.
C: Levels of p-IR and p-AKT in CHO-K1 cells exposed to insulin with or without ACEA. D: Effects of CB1R over-expression on insulin-stimulated IR
autophosphorylation. CHO-IR cells transiently transfected with the indicated plasmids were preincubated with ACEA for 20 min before insulin
treatment (10 min), after which their lysates were subjected to Western blot analysis for the indicated proteins. E: Substitution of IR auto-
phosphorylation sites (Tyr1158/1162/1163) with Ala. F: Western blot analysis for the indicated proteins in b-IRKO cells exposed to ACEA for 40 h
after transfection with empty vector, IR-WT, or IR-3YA. (A high-quality color representation of this ﬁgure is available in the online issue.)
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degradation, and the capacity to generate ECs in response
to glucose stimulation and depolarization, even when iso-
lated from the pancreas. We used several antibodies
(33,34), including the L15 antibody to the C-terminus of
CB1R that exhibits the expression pattern most consistent
with in-situ hybridization (33) as well as qRT-PCR of laser-
captured b-cells from islets, to afﬁrm that CB1Rs, but not
CB2Rs, are present on b-cells of mice and men. Bermúdez-
Silva et al. (14) have very recently written that using the
L15 antibody they also found a CB1R signal with insulin
costaining; after using a commercially available CB1R an-
tibody, they reported that CB1Rs were mainly expressed in
a-cells (10). CB2Rs are absent from a- and b-cells. Most
reports, including this study, found that b-cells contain EC
synthetic and degrading enzymes (9–11,14).
Since at least 1979, insulin mediators, also referred to as
insulin second messengers, are known to be generated
from lipid precursors present on plasma membranes in
response to IR activation and consequent downstream
phospholipase activation (35). We are now suggesting that
ECs, also generated from lipid precursors in b-cells, in-
ﬂuence IR activation (Supplementary Fig. 3). This is es-
pecially relevant because insulin concentrations would be
expected to be at their highest levels surrounding b-cells
and therefore the islet ECS potentially evolved to prevent
an over-exuberant b-cell IR signaling cascade. Favoring
this view are our ﬁndings that in various b-cell lines,
isolated islets and a mouse model of diabetes CB1R sig-
naling counteracts the effects of insulin on b-cells by
preventing IR autophosphorylation and downstream sig-
nals. This ﬁnding was not unique to pancreatic b-cells
because activation of CB1Rs also impeded exogenous
insulin-stimulated IR autophosphorylation in non-insulin-
secreting cells.
We also found that Gai, which is involved in the regu-
lation of insulin secretion (36) and b-cell proliferation (37),
mediates the inhibitory effect of CB1R activation on IR
activity by its association with IR. CB1R activation increased
Gai3 activity and Gai3/IR association was strengthened by
CB1R activation and substitution of Tyr1158/1162/1163
residues of IR with Ala, which, conversely, was weakened
by suppression of CB1R activity and by insulin. Further-
more, knockdown of Gai3 by siRNA abolished the ability of
CB1R to inhibit exogenous insulin-stimulated IR auto-
phosphorylation and b-cell proliferation.
These results suggest a functional and physical crosstalk
between CB1R and IR signaling upon IR autophosphor-
ylation in a Gai-dependent manner. Given that binding of
insulin to the extracellular a-chains of IR causes a change
FIG. 7. Activation of CB1Rs increases the association between Gai3 and IR. A: Immunostaining for Gai and Gai3 in human and mouse islets. Anti-
Gai antibody recognizes Gai1,G ai2,a n dG ai3. Scale bar = 50 mm. B:G ai activation assay in b-IRWT and b-IRKO cells. Lysates of b-IRWT and b-IRKO
cells treated with or without ACEA (10 mmol/L) for 20 min were subjected to immunoprecipitation with anti-Gai-GTP and to immunoblotting with
anti-Gai3. For positive control, b-IRWT cell lysate not treated with ACEA was incubated with GTP-gS for 90 min before immunoprecipitation.
C: Endogenous Gai3/IR interaction in b-IRWT cells exposed to ACEA or vehicle (15 min) after transfection of the indicated siRNAs. D: Endogenous
Gai3/IR interaction in b-IRWT cells exposed to insulin (10 nmol/L) with or without ACEA (10 mmol/L). E: Western blot analysis for the indicated
proteins in b-IRKO cells exposed to ACEA (10 mmol/L) for 15 min after transfection with empty vector, IR-WT, or IR-3YA. F: Increase of Gai3/IR
interaction by ACEA in b-IRKO cells of cohorts in E. G: Reduction of Gai3/IR interaction by AM251 in b-IRKO cells transfected with empty vector,
IR-WT, or IR-3YA. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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phosphorylation sites of one b-chain within reach of the
active site of the other b-chain and that results in auto-
phosphorylation at Tyr1158/1162/1163 residues in the ac-
tivation loop of the b-chains (38,39), we propose that Gai3
activated by CB1R associates with unphosphorylated IR at
the Tyr1158/1162/1163 residues, preventing a conforma-
tional change that secures the activation loop in a catalyt-
ically competent conﬁguration upon ligand binding.
Because these receptors are found to be present within
caveolae, a cholesterol-rich microdomain that performs
a number of signaling functions (40), it is possible that the
closeness of the CB1Rs causes them to be involved in
modulating IR-mediated signaling. Although the detailed
molecular mechanism underlying CB1R and Gai3 as regu-
latory components in the IR signaling pathway awaits
further exploration, collectively, our results imply that the
alteration in IR activity by CB1Rs is a reﬂection of a direct
inhibition of IR autophosphorylation in a Gai-dependent
manner and that ECs directly regulate proliferation
through activation of CB1Rs expressed in b-cells. Through
these actions, CB1Rs are likely to set a threshold level for
IR-mediated responses, which depends on the level of
expression or activation of CB1R. Alteration in IR activ-
ity by CB1Rs may additionally be due to the change in
autocrine activation because of altered insulin secretion.
CB1R-mediated suppression of insulin secretion in a
Ca
2+-dependent manner has been reported (12,41); how-
ever, there are also reports to the contrary (9,10,15,42,43).
We demonstrate the therapeutic advantage of CB1R
modulation in a type 2 diabetic condition. Inhibition of
CB1R activity in db/db mice led to reduced blood glucose
and increased b-cell proliferation, coupled with enhanced
IR signaling. There is also evidence that insulin itself
reduces glucose-stimulated EC synthesis in b-cells, which
would serve as a negative feedback loop to reduce intra-
islet EC levels (9). This would logically mean that when IR
function is reduced, as in type 2 diabetes, such a robust
feedback would also be impaired, leading to nonphysiologic
EC levels in islets (in addition to in fat and liver) and con-
sequent CB1R-mediated b-cell dysfunction through further
impeding IR activity. Blocking CB1Rs would therefore be
expected to improve b-cell function in db/db mice, as we
found. CB2R antagonism had no such effects.
An inadequate expansion of b-cell mass or failure of the
existing b-cell mass to compensate for the changing insulin
demand are hallmarks of type 2 diabetes, and these prom-
inent features may result from defective IR signaling (1–4,27–
29). Therefore, our data should result in the resumption of
attention being paid to ECS as a key factor in b-cell physi-
ology and may lead to development of a new therapeutic
strategy aiming to preserve better functioning b-cells.
FIG. 8. Inhibitory effects of CB1R on IR signaling require Gai. A:E f f e c t so fG ai3 over-expression on p-IR and p-IRS1/2 in b-IRWT cells. B:P h o s -
phorylation of IR, IRS1/2, and AKT in b-IRWT cells exposed to insulin (10 nmol/L) with ACEA (10 mmol/L) or vehicle after transfection of the in-
dicated siRNAs. C: Level of p27 in b-IRWT cells exposed to ACEA for 40 h after transfection of the indicated siRNAs. D:C o m p a r i s o no ft h e
proliferation rate between b-IRWT cells transfected with scramble, CB1R, or Gai3 siRNA. The relative proliferation rate of b-IRWT cells was de-
termined 3 days after transfection. Data are shown as the mean 6 SEM from three independent experiments. **P < 0.01. E: Effects of ACEA on the
proliferation of b-IRWT cells transfected with the indicated siRNAs. Data are shown as the mean 6 SEM from three independent experiments. **P <
0.01 vs. vehicle; #P < 0.05; ##P < 0.01 vs. scramble siRNA.
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the pancreas, are said to be elevated in diabetes and obesity
(9,11,44,45), and elevated EC levels are associated with in-
creased DAGLa and decreased FAAH levels in b-cells (11).
Thus, it is possible that increased EC tone (due to increased
EC synthesis, receptor expression or activity) affects the
well-described glucose-unresponsiveness of b-cells and the
development of insulin resistance by impeding IR auto-
phosphorylation in insulin-sensitive tissues. Indeed, AEA
was recently found to impair insulin-stimulated AKT phos-
phorylation and decrease glucose uptake in skeletal muscle
cells (7), and CB1R antagonism enhanced insulin respon-
siveness of skeletal muscle (8).
In addition, pharmacologic blockade of CB1R in obese
fa/fa Zucker rats decreased blood glucose levels and pre-
served b-cell mass (46), and eliminating CB1Rs in liver
protected against fatty liver and improved glucose toler-
ance and insulin sensitivity in high-fat diet–fed mice (23);
IR function in those mice was not investigated. Peripheral,
but not central, blockade of CB1R was recently reported to
improve overall insulin sensitivity and glucose homeosta-
sis (26) and a non-brain-penetrant CB1R antagonist im-
proved glucose homeostasis, insulin sensitivity, and fatty
liver in a weight-independent manner (25). This is a very
important point, because a centrally acting CB1R antago-
nist, rimonabant, used for treating obesity, was removed
from patient use because of potentially life-threatening
psychiatric problems (47). Therefore, CB1R antagonists
with poor brain penetrance might be useful therapies in
type 2 diabetes where they would be expected to lessen
insulin resistance in skeletal muscle and liver, ameliorate
or prevent fatty liver, and improve b-cell function/pro-
liferation.
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